How to buy Fortress Biotech stock (FBIO)

Fortress Biotech is a biotechnology business based in the US. Fortress Biotech shares (FBIO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.77 – a decrease of 11.06% over the previous week. Fortress Biotech employs 186 staff and has a trailing 12-month revenue of around $82.6 million.

Our top picks for where to buy Fortress Biotech stock

Buy Fortress Biotech stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Fortress Biotech stock price (NASDAQ: FBIO)

Use our graph to track the performance of FBIO stocks over time.

Fortress Biotech shares at a glance

• Key figures

Information last updated 2024-12-15.

Latest market close	$1.77
52-week range	$1.36 - $4.43
50-day moving average more info button	$1.72
200-day moving average more info button	$1.86
Wall St. target price	$14.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-27.73

Is it a good time to buy Fortress Biotech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Fortress Biotech price performance over time

Historical closes compared with the close of $1.82 from 2024-12-17

1 week (2024-12-12)	-8.54%
1 month (2024-11-20)	15.92%
3 months (2024-09-19)	-1.09%
6 months (2024-06-18)	1.68%

1 year (2023-12-19)	-24.79%
2 years (2022-12-19)	-77.94%
3 years (2021-12-17)	37.8
5 years (2019-12-19)	34.05

Fortress Biotech financials

Revenue TTM	$82.6 million
Gross profit TTM	$-85,658,000
Return on assets TTM	-36.41%
Return on equity TTM	-1739.64%
Profit margin	-49.25%
Book value	$0.79
Market Capitalization more info button	$46.9 million

TTM: trailing 12 months

Fortress Biotech share dividends

We're not expecting Fortress Biotech to pay a dividend over the next 12 months.

Have Fortress Biotech's shares ever split?

Fortress Biotech's shares were split on a 1:15 basis on 9 October 2023 . So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Fortress Biotech shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Fortress Biotech shares which in turn could have impacted Fortress Biotech's share price.

Fortress Biotech share price volatility

Over the last 12 months, Fortress Biotech's shares have ranged in value from as little as $1.36 up to $4.43. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Fortress Biotech's is 1.746. This would suggest that Fortress Biotech's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Fortress Biotech overview

Fortress Biotech, Inc. , a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc.

Frequently asked questions

null
What percentage of Fortress Biotech is owned by insiders or institutions?
Currently 21.21% of Fortress Biotech shares are held by insiders and 14.463% by institutions. How many people work for Fortress Biotech?
Latest data suggests 186 work at Fortress Biotech. When does the fiscal year end for Fortress Biotech?
Fortress Biotech's fiscal year ends in December. Where is Fortress Biotech based?
Fortress Biotech's address is: 1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154 What is Fortress Biotech's ISIN number?
Fortress Biotech's international securities identification number is: US34960Q1094 What is Fortress Biotech's CUSIP number?
Fortress Biotech's Committee on Uniform Securities Identification Procedures number is: 21976U109